Home / News / Company Statements / Biocon Biologics’ Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated (VAI)
Bengaluru, Karnataka, India, Oct 30, 2024
“The U.S. Food and Drug Administration (FDA) has classified Biocon Biologics’ Drug Substance Facility at Biocon Campus, (Site 1) located in Bengaluru, Karnataka, as Voluntary Action Indicated (VAI).
This relates to the cGMP inspection conducted by the agency between February 20-28, 2024 and pertains to the supply of rh-Insulin (rhI) Drug Substance to the United States.
Biocon Biologics remains committed to global standards of Quality and Compliance.”
– Company Spokesperson
Biocon Biologics Inc. assumes no responsibility for and makes no warranties or representations of any kind as to the accuracy, currency, or completeness of any information contained in such third-party website, including any third-party social media or mobile application platform. Inclusion of any third-party link on this website does not imply an endorsement or recommendation by Biocon Biologics, and a link to this website from another website does not imply a relationship between Biocon Biologics and any third party. Your use of any such third-party site or platform is at your own risk and will be governed by such third party’s terms and policies (including its privacy policy). Biocon Biologics shall not be liable for any direct, indirect, consequential, incidental, or punitive damages arising out of access to, use of, or inability to use such third-party website, or any errors or omissions in the content thereof.